SCHEMBL14645324

SCHEMBL14645324

COC(=O)Cc1ccsc1-c1ccc(-c2sc(C(=O)c3ccccc3)cc2CC(=O)OC)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.38
KMT2A Q03164 5/20 0.38
MAPK1 P28482 2/20 0.38
TP53 P04637 2/20 0.38
ALOX15 P16050 1/20 0.38
HPGDS O60760 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 4/20 0.35
LMNA P02545 3/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPT P10636 3/20 0.35
TDP1 Q9NUW8 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14645336 0.92 NPSR1 (0.43) NPSR1KMT2AMAPK1NPC1RAB9A
SCHEMBL14646277 0.88 KMT2A (0.44) KMT2AMAPK1TP53ALOX15HPGDS
SCHEMBL14645236 0.87 RAB9A (0.41) NPSR1KMT2AMAPK1TP53ALOX15
SCHEMBL14646181 0.82 KMT2A (0.41) KMT2AMAPK1TP53ALOX15NPC1
SCHEMBL16893413 0.81 MAPT (0.46) NPSR1KMT2AMAPK1TP53NPC1
SCHEMBL14645403 0.81 RAB9A (0.45) KMT2AMAPK1TP53ALOX15HPGDS
SCHEMBL14645340 0.79 KMT2A (0.36) NPSR1KMT2AMAPK1TP53ALOX15
SCHEMBL14645455 0.79 KMT2A (0.34) KMT2AMAPK1TP53ALOX15NPC1
SCHEMBL15695286 0.79 KMT2A (0.37) KMT2AMAPK1TP53ALOX15HPGDS
SCHEMBL15695224 0.78 KMT2A (0.38) KMT2AMAPK1TP53ALOX15NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 EP disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 NPSR1 2158/4885KMT2A 4329/4885MAPK1 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.